Share the Video:

The State of Psychedelic Research Since 2017

Paul Summergrad, Tom Insel, Rachel Nuwer

The science of psychedelics has come a long way since Drs. Summergrad and Insel met on our stage in 2017. Research into psychedelics has boomed, but six years later fundamental questions remain about mechanisms, efficacy, and policy. Are psychedelics medications for people with a diagnosis or agents to facilitate personal growth? What does the science tell us about benefits and risks? What do we know about the role of psychotherapy or practitioner training ? How should these compounds be regulated? Are there conditions or circumstances that increase the risk of adverse outcomes? Does FDA approval matter? How important is deep experience for providers? And if so, what types of experiences matter? In this session, two of the nation’s psychiatric thought leaders will discuss these questions and more.

Become a MAPS Member with a monthly donation

As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.

Who can be a psychedelic practitioner?

Discussion on suitability for practicing psychedelic care professionally, and introduction of a project to advance the field.

Andrew Penn, Mary Cosimano

PS2023 Integration Policy and Advocacy Psychedelic Assisted Therapy Psychedelic Science Research Resources for Therapists

Improving study design in trials using psychedelic-assisted therapies

Psychedelic research faces challenges balancing methodological rigor with preserving subjective experiences in clinical trials, aiming to avoid bias while capturing the full impact of psychedelics on participants.

Ingmar Gorman, Erika Dyck, Tehseen Noorani

PS2023 MDMA Policy and Advocacy Psychedelic Assisted Therapy Psychedelic Science Research Research and Science

Priorities for the next generation of psychedelic science

NIMH Director Joshua A. Gordon and trauma researcher Barbara O. Rothbaum discuss the current state and future directions of psychedelic research, emphasizing the need for deeper understanding and robust study

Joshua A Gordon

PS2023 Policy and Advocacy Psychedelic Assisted Therapy Psychedelic Science Public Benefit Research Research and Science

What Will People Think? Revealing Public Knowledge, Belief, and Perceptions of Psychedelics

Imran Khan presents findings of the Psychedelic Insight Poll, a national survey by the Berkeley Center for the Science of Psychedelics to understand public perceptions of psychedelic substances. The poll

Imran Khan

PS2023 Health Equity Policy and Advocacy Psychedelic Assisted Therapy Psychedelic Science Research Research and Science

Group sessions can make psychedelic treatment more accessible: Empirical evidence

Dr. Smith and Dr. Jones analyze the economic impact of drug pricing and care costs on the psychedelic market at PS2023.

PS2023 Business Policy and Advocacy Psychedelic Assisted Therapy Psychedelic Science Public Benefit Research and Science

The evolving financial landscape for psychedelic medicine

Funding for psychedelic medicine is evolving, with a rise in commercial capital alongside philanthropic support. Balancing financial interests with equitable access and learning from scaling challenges are key considerations.

Henry Elkus

PS2023 Business Policy and Advocacy Psychedelic Science Research Research and Science

The state of the psychedelic sector

Hardman provides a quick overview of the emerging psychedelic sector, covering financial, research, and policy landscapes with data visuals. He also explores unanswered questions about the sector's future.

Josh Hardman

PS2023 Harm Reduction Integration Policy and Advocacy Psychedelic Assisted Therapy Psychedelic Science Research

Responding to Crises and Calls with Psychedelic Harm Reduction

Panelists from Zendo Project, Fireside Project, Kosmicare, and Anashim Tovim discuss harm reduction strategies in the psychedelic ecosystem, emphasizing innovation, compassion, and scientific expertise in diverse settings. They provide case

Joshua White, Daniel E Martin, Pinni Baumol, Shirelle Noble, Ben Halper

PS2023 Policy and Advocacy Psychedelic Assisted Therapy Psychedelic Science Research Social and Cultural Spirituality

Tempering Psychedelics: A Conversation with Michael Pollan and Bob Jesse

Michael Pollan, an influential author, sparked interest in psychedelic research with his book "How to Change Your Mind." Bob Jesse, a key figure in the resurgence of psychedelics, has made

Robert Jesse, Michael Pollan

The State of Psychedelic Research Since 2017

Become a MAPS Member with a monthly donation

Related Videos